Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, GENFIT will advance Celloram’s first-in-class inflammasome inhibitor, CLM-022, a triterpenoid derivative that targets the inflammasome machinery, in liver disease indications.
Lead Product(s): CLM-022
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CLM-022
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genfit
Deal Size: $175.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 31, 2023